“…Based on our previously published results [13][14][15]20] and the above evidence, we propose enriching LIFRa-CT3 and thus activating pSTAT3 in the cytoplasm to induce effects, similar to normal or reduced doses of ATRA-based therapy, in leukemia cells (Fig. 1).…”